Introduction
Transformation of normal cells usually requires two or more cooperative oncogenic events. The combination of c-myc and activated ras was the ®rst pair of characterized genes to show oncogenic cooperation (Land et al., 1983) , which has been observed in many types of cells (Morgenbesser and DePinho, 1994; Henriksson and LuÈ scher, 1996) . However, there have been few direct approaches using cells transformed by myc and activated ras to investigate the mechanism of their oncogenic cooperation, which is still poorly understood.
Growth-factor-independent expression of myc occurs in many tumor cells as a result of either lesions in the myc gene itself or mutations in signaling pathways that regulate myc expression (Bouchard et al., 1998) . myc positively regulates cell cycle progression, which appears to be important for tumorigenesis by myc. myc also activates cell death, apoptosis. It is well established that myc causes apoptosis under serumstarved conditions (Evan et al., 1992; Evan and Littlewood, 1993; Hunter, 1997) . However, it is unclear whether the activity that causes apoptosis is involved in establishment of transformation by myc and ras.
Mutated ras genes that produce constitutively activated Ras proteins have been widely observed in human cancers (Bos, 1989) . Activated Ras activates Raf (MAP kinase kinase kinase), which activates MAP kinase/ERK (MAPK/ERK) via MEK (MAPK/ERK kinase) (Lowy and Willumsen, 1993) . These reactions constitute the Ras/MAPK signaling cascade, which is involved in regulation of cell proliferation and apoptosis. Recently it was reported that other signaling cascades, including PI3 kinase (PI3K) signaling (Hu et al., 1995) , are controlled downstream of Ras, and that c-myc-dependent apoptosis under serum-starved conditions can be blocked by a constitutively active PI3K mutant, but not by a constitutively active Raf mutant (Kaumann-Zeh et al., 1997) . In cells transformed by myc and activated ras, however, it is unclear which cascade or cascades play crucial roles, and which function or functions Ras exerts.
To investigate the mechanism of malignant transformation, it is useful to compare transformed cells and non-transformed cloned parent cells, and it is a great help to be able to suppress activity of the oncogenes in the transformed cells. Rat ®broblast 3Y1 is a cloned cell line that retains in vivo characteristics, including regulated growth and a diploid karyotype (Kimura et al., 1975; Yamashita et al., 1980) . We had observed that 3Y1 cells are malignantly transformed by co-transfection of myc and activated ras, but not by either myc or activated ras alone (Tsuneoka and Mekada, 1998) . This is consistent with results in transgenic animals and rodent primary embryonic ®broblasts.
Here we describe isolation of a 3Y1 transformed cell line, in which activation of c-Myc and Ras are independently controllable. Using these cells, we found that myc-dependent apoptosis is suppressed by activated Ras. Ras/MEK signaling is crucial for suppressing apoptosis in these transformed cells. Furthermore, we observed oncogenic cooperation between c-myc and other genes that activate MEK activity, including activated raf, mos, and activated mek1 itself. MEK activity suppresses apoptosis in cells transformed by these genes. We also show evidence that the regulatory mechanism by which inhibition of MEK activity initiates apoptosis is distinct from the one by which c-myc-dependent apoptosis is triggered in serum-starved conditions.
Results

A transformed cell line in which activation of c-Myc and v-Ras are independently controllable
To investigate the roles of c-myc and ras in transformation, we isolated a transformed 3Y1 cell line, MEtR1-2, in which activation of c-Myc and v-Ras were controllable (Figure 1 ). c-Myc was expressed in the form of c-MycER, a chimeric protein of c-Myc and part of the estrogen receptor, whose activity is stimulated by estrogen or the estrogen-like molecule 4-hydroxy tamoxifen (OHT) (Eilers et al., 1989; Tsuneoka et al., 1997) . OHT control of c-MycER activity was veri®ed by measuring its eect on expression of the c-myc target gene RCC1 (Tsuneoka et al., 1997) in the transformed cells. OHT increased expression of luciferase activity from an RCC1 reporter plasmid containing Myc binding elements by 2.5-fold, while it did not increase expression from a control plasmid lacking the Myc binding elements. OHT also elevates expression of RCC1 protein in MEtR1-2 cells (Figure 2a ). The v-ras gene was expressed under a doxycycline stimulated promoter (Gossen et al., 1995) . The activation of v-Ras expression by doxycycline (Dox) was con®rmed by Western blotting using anti Ras antibody (Figure 2a) . When MEtR1-2 cells were seeded in soft agar, colonies were formed only in the presence of both OHT and Dox (Figure 2b) , showing that activity of both oncogene products is necessary to maintain the transformed state.
Removal of activated Ras initiates apoptosis
When MEtR1-2 cells in the transformed state were cultured in the presence of Dox and OHT to maintain the activity of c-Myc and v-Ras, the number of cells increased fourfold within 54 h (Figure 3b ). In the absence of Dox, with OHT, however, there was almost no proliferation. Many shrunken and¯oating MEtR1-2 cells were observed (Figure 3a) , and the cell number decreased signi®cantly (Figure 3b ). These results show that MEtR1-2 cells in the transformed state undergo cell death when c-Myc activity is not accompanied by v-Ras expression. Next, we tested whether apoptosis is Figure 1 The strategy to control activities of c-myc and v-ras. cMyc was expressed in the form of c-MycER, a chimeric protein of c-Myc and part of the estrogen receptor. Activity of the protein is stimulated by estrogen or the estrogen-like molecule 4-hydroxy tamoxifen (OHT) (Eilers et al., 1989; Tsuneoka et al., 1997) . The v-ras gene was expressed under a doxycycline-stimulated promoter (Gossen et al., 1995) . Expression of v-ras is stimulated by doxycycline (Dox). Cells are maintained in the presence of Dox and estrogen to maintain activity of both c-Myc and activated Ras Oligonucleosomal DNA ladders and the proportion of cells with sub-G1 DNA content were reduced to low levels in the absence of both OHT and Dox (Figure 3c, d ). When cells initially maintained with Dox in the absence of the Myc activator (OHT) for 1 day were transferred to the medium without Dox, we detected even less evidence of oligonucleosomal DNA ladders, compared to when Myc activator and Dox were withdrawn simultaneously (data not shown). Therefore, apoptosis initiated by removal of activated Ras is dependent on c-Myc activity. This myc-dependent apoptosis occurs in the presence of fresh serum, without any other factors or reagents to prevent cell proliferation or to cause apoptosis, and in cells adhering to the substrate.
In the presence of OHT, 3Y1ME-7 cells that are expressing c-mycer (Tsuneoka et al., 1997) proliferated as rapidly as parental 3Y1 cells did (Figure 3b) , and oligonucleosomal DNA ladders were not detected when 3Y1ME-7 cells with OHT were maintained in MEtR1-2 cells in the transformed state were cultured in the presence (.) or absence (*) of 1 mg/ml Dox, with 0.1 mM OHT and the number of non-shrunken cells was counted at intervals up to 54 h. 3Y1ME-7 cells (&) (Tsuneoka et al., 1997) expressing only c-MycER were cultured in the presence of 0.1 mM OHT and the cell number was counted at times up to 54 h. Proliferation of the parental 3Y1 cells (D) were also examined. (c) MEtR1-2 cells in the transformed state and 3Y1ME-7 cells were cultured for 24 h in the presence or absence of 1 mg/ml Dox, and/or 0.1 mM OHT. Low molecular weight DNA was collected and electrophoresed in 1.3% agar. (d) MEtR1-2 cells in the transformed state were cultured for 24 h in the presence or absence of 1 mg/ ml Dox, and/or 0.1 mM OHT. DNA content was measured using a¯ow cytometer the presence of serum (Figure 3c ). These results suggest that continued expression of activated ras is required for suppressing apoptosis speci®cally in cells transformed by c-myc and activated ras.
Ras/MEK signaling suppresses apoptosis MAPK/ERK kinase (MEK), one class of kinase downstream from Ras, phosphorylates MAP kinases (ERK1/2) (Lowy and Willumsen, 1993) . When v-Ras is expressed in MEtR1-2 cells (+Dox), the amount of phosphorylated MAPKs is higher than when Dox is withdrawn (Figure 4a ). These results con®rm that MEK is downstream of Ras in MEtR1-2 cells. The eect of inhibition of MEK activity on MEtR1-2 cells was tested to determine whether the protective eect of v-ras is mediated through MEK. The MEK inhibitor, PD098059 (Dudley et al., 1995) , decreased the level of phosphorylated MAPKs but not total MAPKs (data not shown). When the MEK inhibitor was present, the protective eect of v-ras was reduced, and apoptosis of MEtR1-2 cells occurred ( Figure 4b ). DNA ladders were also observed in cell line CR-1 that is transformed by constitutively active c-myc and v-ras when the MEK inhibitor was added ( Figure 7 ).
When activated Mek1 was expressed in MEtR1-2 cells, withdrawal of Dox did not induce apoptosis ( Figure 4c ). Control expression vector (Figure 4c ) or expression of wild type Mek1 (data not shown) did not prevent the apoptosis caused by withdrawal of Dox.
Twenty-four hours and 54 h after MEtR1-2 cells were cultured without Dox in the presence of OHT, cell numbers were reduced to 54 and 13%, respectively, compared to cultures with Dox and OHT (Figure 3b ). On the other hand, 24 and 54 h after MEtR1-2Mek1DE-2 were cultured without Dox in the presence of OHT, cell numbers were 97 and 108%, respectively, compared to cultures with Dox and OHT. These results indicate that activated Mek1 really suppresses cell death of MEtR1-2 cells by withdrawal of Dox. Together, these results demonstrate that Ras/ MEK signaling prevents apoptosis in the transformed cells.
In the absence of OHT, only a low level of apoptosis resulted from treatment of MEtR1-2 cells with the MEK inhibitor (data not shown). To further con®rm the involvement of c-Myc in the apoptosis, we isolated a cell line, rtetCR-2, consisting 3Y1 cells transformed by c-myc under a doxycycline-responsive promoter and v-ras. In these cells, expression of c-Myc is stimulated by Dox (Figure 5a ). The cells produced colonies only in the presence of Dox (data not shown). When MEK inhibitor (PD098059) was present, the amount of phosphorylated MAPK was reduced, and apoptosis of rtetCR-2 cells occurred ( Figure 5b ). When expression of c-Myc is suppressed by withdrawal of Dox, formation of oligonucleosomal DNA ladders by the MEK inhibitor was reduced to a lower level ( Figure  5b ), providing additional evidence that c-Myc is involved in apoptosis initiated by inhibition of Ras/ Figure 4 Eect of MEK activity on apoptosis. (a) MEtR1-2 cells in the transformed state were cultured for 13 h or 25 h in the presence or absence of 1 mg/ml Dox, with 0.1 mM OHT. Ras, phosphorylated MAPKs (P-MAPKs) and total MAPKs were detected by Western blotting. (b) MEtR1-2 cells in the transformed state were cultured for 24 h in the presence of Dox and OHT, with 30 mM PD098059 or with 0.1% DMSO (vehicle for PD098059), and then low molecular weight DNA was collected and electrophoresed in 1.3% agar. (c) MEtR1-2 cells carrying control vector (MEtR1-2 vector) and MEtR1-2 cells expressing activated Mek1 (MEtR1-2Mek1DE-2) were cultured for 24 h in the presence or absence of 1 mg/ml Dox, with 0.1 mM OHT, and then apoptosis was detected as in b Figure 5 Myc-dependent apoptosis initiated by MEK inhibitor. (a) rtetCR-2 cells are 3Y1 cells transformed by c-myc under control of a Dox-stimulated promoter and v-ras. Cells in the transformed state were cultured for 24 h in the presence or absence of 1 mg/ml Dox (c-Myc inducer). c-Myc protein was analysed by Western blotting using rabbit anti c-Myc antibody. Total proteins were also stained. (b) Upper: rtetCR-2 cells in the transformed state were cultured for 6 h in the presence or absence of Dox, and further cultured with 30 mM PD098059 or with 0.1% DMSO (vehicle for PD098059) for 18 h, and then phosphorylated MAPK and MAPK were analysed by Western blotting. Lower: rtetCR-2 cells in the transformed state were cultured for 6 h in the presence or absence of Dox, and further cultured with 30 mM PD098059 or with 0.1% DMSO for 24 h, and then low molecular weight DNA was collected and electrophoresed in 1.3% agar MEK signaling in cells transformed by c-myc and vras. The result also con®rms that apoptosis does not result from Dox exposure and withdrawal.
Apoptosis initiated by MEK inhibitor is unique to cells transformed by c-myc plus a gene that activates MEK Activated Mek1 completely blocked apoptosis initiated by removal of v-Ras in MEtR1-2 cells (Figure 4c ). We therefore examined whether activation of MEK was sucient for oncogenic cooperation with myc to transform cells, i.e. whether activation of MEK could replace the requirement for activated Ras. We investigated the transforming activity of various genes in rat ®broblast cell line 3Y1. While transfection of cmyc, v-ras or activated raf alone was not eective, cotransfection of c-myc with v-ras or activated raf eciently produced colonies in soft agar ( Figure 6 ) and foci in cell culturing dishes (Table 1) , which is consistent with previous reports (Land et al., 1983; Bechade et al., 1985; Pfeifer et al., 1989; Tsuneoka and Mekada, 1998 ). An oncogene, mos, also activates MEK (Hunter, 1997) . It had been reported that malignant transformation by mos does not require c-Myc activity in some type of cell line used (Sawyers et al., 1992) . However, transfection of mos alone did not transform 3Y1 cells, while cells were transformed by cotransfection with mos and c-myc. We also observed oncogenic cooperation between c-myc and activated mek1, which had not been reported. Thus, all genes examined here that activate MEK together with c-myc transform 3Y1 cells, suggesting that constitutive activation of MEK is sucient to cooperate with cmyc to malignantly transform cells. We also observed oncogenic cooperation between cyclin E and v-ras in 3Y1 cells (Table 1) , which is consistent with a previous report using rat embryonic ®broblasts (Haas et al., 1997) .
Next we studied whether MEK activity plays a critical role to suppress apoptosis of cell lines that were transformed by the above genes. MEK activity was reduced by the MEK inhibitor PD098059 in all clones used here, as judged by the amount of phosphorylated MAPKs (data not shown). In cell lines transformed by c-myc and v-ras (MEtR1-2 and CR-1), c-myc and activated raf (Mraf-1), and c-myc and mos (MM-1), the MEK inhibitor caused apoptosis (Figures 7 and 4) . PD098059 also caused apoptosis of cells transformed ; (e) activated raf expression vector and c-myc expression vector, (f); activated mek1 expression vector and pCDM8, (g); activated mek1 expression vector and c-myc expression vector; (h) mos expression vector and pCDM8 (i) mos expression vector and c-myc expression vector. c-myc was expressed in pCDM8 vector. v-ras is expressed in p4E. pXb is a control vector which has no transformation activity. Activated raf, activated mek1, and cyclin E were expressed in pactEF vector. c-mos was expressed in pML vector 3Y1 cells were transfected with oncogenes described above and were cultured for 2 weeks. The numbers of foci were scored by staining with Giemsa's solution. c-myc was expressed in pCDM8 vector. p4E is the v-ras expression vector and pXb is a control vector which has no transformation activity (Tsuchida et al., 1982; Tsuneoka and Mekada, 1998) . Activated raf, activated mek1 and cyclin E were expressed in pactEF vector. c-mos was expressed in pML vector by c-myc and a gene coding activated Mek1 itself (MEM-1). On the other hand, in parental 3Y1 cells, and cells transformed by cyclin E and v-ras (CycExRas-1 and CycExRas-2), apoptosis was not caused by the MEK inhibitor ( Figure 7) .
Apoptosis under serum-starved conditions
It is well established that c-myc causes apoptosis in serum-starved conditions (Evan et al., 1992; Evan and Littlewood, 1993; Hunter, 1997) . When serum was reduced to 0.5% in the medium of MEtR1-2 cells in the transformed state, cells underwent c-Myc-dependent apoptosis (Figure 8a ). Therefore, activated Ras ± 7) , and MEtR1-2 expressing activated Mek1 (MEtR1-2Mek1DE-2) (lanes 8 ± 11), all in the transformed state, were cultured for 24 h under various conditions, and low molecular weight DNA was collected and electrophoresed in 1.3% agar. Cells in lanes 1, 4 and 8 were cultured in the presence of 1 mg/ ml Dox, 0.1 mM OHT, and 10% serum; lanes 2, 5 and 9 in the presence of 1 mg ml Dox, 0.1 mM OHT, and 0.5% serum; lane 3 in presence of 1 mg/ml Dox and 0.5% serum without OHT; lanes 6 and 10 in the presence of 0.1 mM OHT and 10% serum without Dox; lanes 7 and 11 in the presence of 0.1 mM OHT and 0.5% serum without Dox. (b) Eects of overexpression of chicken bcl-xL on apoptosis. MEtR1-2 cells carrying a control vector (lanes 1 ± 4), MEtR1-2 cell lines stably expressing chicken bcl-xL, MEtR1-2cbcl-xL-1 (lanes 5 ± 8) and MEtR1-2cbcl-xL-2 (lanes 9 ± 12) with activated c-Myc (0.1 mM OHT) were cultured for 24 h under various conditions, and then low molecular weight DNA was collected and electrophoresed in 1.3% agar. Cells in lanes 1, 5 and 9 were cultured in the presence of 1 mg ml Dox and 10% serum; lanes 2, 6, and 10 in the presence of 1 mg/ml Dox, 10% serum and 30 mM PD098059; lanes 3, 7, and 11 in the absence of Dox and in the presence of 10% serum; lanes 4, 8, and 12 in the presence of 1 mg/ml Dox and 0.5% serum does not prevent myc-dependent apoptosis under serum-limiting conditions. The combination of serum deprivation and removal of v-Ras expression caused more pronounced apoptosis than either serum deprivation or removal of v-Ras expression alone (Figure 8a ). This additive eect was also observed between MEK inhibition and serum deprivation (data not shown). Activated Mek1 expression blocked apoptosis initiated by removal of v-Ras expression (Figures 4c  and 8a ). On the other hand, apoptosis caused by serum deprivation was enhanced, rather than suppressed, by activated Mek1 expression (Figure 8a ). This result is consistent with a previous report in which a constitutively activated Raf, which activates MEK, increased c-myc-induced apoptosis under serum-limiting conditions (Kaumann-Zeh et al., 1997 ). An antiapoptotic member of bcl-2 family has been shown to suppress c-myc-induced apoptosis under serum-starved conditions (Evan and Littlewood, 1998) . When chicken bcl-xL was highly expressed in MEtR1-2 cells, although serum deprivation did not cause apoptosis, removal of v-Ras expression or MEK inhibition still caused apoptosis (Figure 8b ).
Discussion
After establishment of the transformed state by c-myc and activated ras, removal of activated Ras initiates apoptosis that is dependent on c-Myc activity. Since a signi®cant population of the transformed cells undergo apoptosis if Ras activity is reduced, suppression of myc-dependent apoptosis by activated Ras is important for maintaining the transformed state.
While it is well established that myc causes apoptosis under sub-optimal conditions for cell proliferation (Evan et al., 1992; Littlewood, 1993, 1998; Hunter, 1997) , the myc-dependent apoptosis initiated by removal of activated Ras occurs under conditions that are generally favorable for cell proliferation, i.e. in the presence of fresh serum, without any other factors or reagents to prevent cell proliferation or to cause apoptosis, and in cells adhering to the substrate. Therefore, conditions for myc-dependent apoptosis initiated by removal of activated Ras are distinct from the well-established ones.
We demonstrated that activated Ras prevents apoptosis through MEK activity in cells transformed by c-myc and activated ras. However, initiation of apoptosis by MEK inhibitor is not a general property of cells. The MEK inhibitor did not initiate apoptosis in the parental cells. When the cells were transformed by c-myc together with v-ras, activated raf, mos, or activated mek1, the MEK inhibitor initiated apoptosis. In cells transformed by cyclin E and v-ras, the MEK inhibitor did not cause apoptosis. Thus, MEK activity plays an indispensable role in suppressing apoptosis speci®cally in cells that are transformed by c-myc together with a gene that activates MEK.
In myc and ras transformed cells, serum deprivation also initiates apoptosis. While activated Mek1 expression blocked apoptosis initiated by removal of activated Ras, apoptosis caused by serum deprivation was not suppressed by activated Mek1. Serum deprivation plus removal of activated Ras or MEK inhibition had additive eects on apoptosis. Overexpression of chicken bcl-xL suppressed apoptosis caused by serum deprivation, but it did not suppress apoptosis by removal of activated Ras or MEK inhibition. These results suggest that apoptosis initiated by inhibition of Ras/MEK signaling involves a distinct regulatory mechanism from apoptosis initiated by serum deprivation. Altogether our results suggest that there is a novel regulatory mechanism for myc-dependent apoptosis, which is important to establish the transformed state by c-myc and activated ras.
Recently it was reported that c-myc-activated apoptosis under serum-limiting conditions can be suppressed by Ras/PI3K signaling (Kaumann-Zeh et al., 1997) . Occurrence of apoptosis by serum deprivation in myc and ras transformed cells, however, suggests that activated ras, if it has any eect, does not have enough activity to suppress apoptosis under serum-limiting conditions in the transformed cells.
3Y1 cells were transformed by c-myc plus activated raf or activated mek1, which is in the Ras/MAPK cascade. These results suggest that activation of other kinase cascades by activated Ras is not required for establishment of the transformed state. Thus, our results suggest that the ability of Ras/PI3K signaling to suppress myc-activated apoptosis under serumlimiting conditions is not important for establishment of the transformed state by myc and activated ras.
Induction of apoptosis is a possible therapy for human cancers (Thornberry and Lazebnik, 1998; Evan and Littlewood, 1998) . We showed here that MEK inhibition induces apoptosis in cells transformed by cmyc plus a gene that activates the Ras/MAPK cascade, but not in non-transformed cells, or cells transformed by cyclin E and v-ras. These results suggest that the MAPK cascade is a potential therapeutic target in a group of cancers in which cooperation of myc and activated Ras/MAPK cascade is implicated.
Materials and methods
Plasmids
The v-ras expression vector p4E and a control vector pXb, which has no transformation activity, have been described previously (Tsuchida et al., 1982; Tsuneoka and Mekada, 1998) . To express v-Ki-ras under control of doxycycline, the 1.2 kb PuvII ± SacII fragment of v-Ki-ras cDNA from p4E was inserted into the XbaI(blunted)-SacII sites of pUHC10-3, which harbors the tetracycline-responsive promoter (Gossen et al., 1995) , to produce ptetv-Ki-ras. To express c-myc under control of doxycycline, the 1.6 kb HindIII (blunted with Klenow Enzyme)-BamHI fragment of human c-myc cDNA from pc-myc/CDM8 (Tsuneoka et al., 1997) was inserted into the EcoRI (blunted with Klenow Enzyme) ± BamHI sites of pUHC10-3, to produce ptetc-myc. For eective control, the 1 kb EcoRI ± BamHI fragment of the cDNA for the transcription factor rtTA from pUDH172neo (Gossen et al., 1995) was inserted into the EcoRI-BamHI sites of pUHC10-3 to generate ptetrtTA. The c-myc expression plasmid, pc-myc/CDM8 and pMLmycer, were described previously (Tsuneoka et al., 1997 Sagata, 1995) , and c-mos expression vector pMLmos, in which mouse c-mos is driven by the Mo-MSV LTP promoter (Okazaki and Sagata, 1995) , were kind gifts from Drs Okazaki and Sagata. Chicken bcl-xL expression vector pCAGGScbcl-xL was a kind gift from Dr Tsujimoto. pActBS that contains a blasticidin resistance gene under control of an actin promoter, and pActHyg that contains a hygromycin resistance gene under control of an actin promoter, were kind gifts from Dr Nakanishi. cDNA for human cyclin E (Ko et al., 1991) was ampli®ed by PCR with 5'-CGCTCTAGACACCATGAAGGAGGACGGCG-GCG and 5'-GCGAGATCTGGAGAAGGATGGGGTG-GTCACGCC as primers, and the ampli®ed 1.2 kbp fragment was cleaved with BglII and XbaI, and ligated with pactEF cut with BamHI and XbaI to produce a cyclin E expression vector pactEFcycE.
Cell lines, cell culture and DNA transfection Rat 3Y1 ®broblasts (Kimura et al., 1975) and their derivatives were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (10FBS-DMEM). DNA transfection was performed by the calcium-phosphate procedure as described previously (Chen and Okayama, 1988) . 3Y1ME-7, a cell line that expresses c-MycER chimeric protein (Tsuneoka et al., 1997) , was transfected with ptetrtTA and ptetv-Ki-ras and grown in soft agar in the presence of 1 mg/ml of doxycycline and 0.1 mM of b-estradiol. Colonies were picked up, dissociated into single cells, and regrown to establish the transformed cell line. The transformed cell line, MEtR1-2, was maintained in 10FBS-DMEM containing 1 mg/ml of doxycycline and 0.1 mM of b-estradiol. To select MEtR1-2 cells expressing an activated mutant of Mek1, MEtR1-2 cells were cotransfected with pactEFmek1 DE together with pActBS, and cultured in medium containing 2 mg/ml blasticidin to isolate a clone MEtR1-2Mek1DE-2. Myc-tagged Mek1 expression was con®rmed by Western blotting using anti Myc tag monoclonal antibody (9E10). To select MEtR1-2 cells highly expressing chicken bcl-xL, MEtR1-2 cells were co-transfected with pCAGGScbcl-xL together with pActBS, and cultured in medium containing 2 mg/ml blasticidin to isolate clones, MEtR1-2cbcl-xL-1 and -2. Chicken bcl-xL expression was con®rmed by RT-PCR using 5'-TGGACCATGGACTCATT-GAG and 5'-CGTGGTGGATGTGTGAAGG as primers. 3Y1ME-7 cells were transfected with pactEFmek1 DE , to establish transformed cell line MEM-1. 3Y1 cells were transfected with pc-myc/CDM8 and v-ras expression vector to establish transformed cell line CR-1, pc-myc/CDM8 and activated raf expression vector to establish transformed cell line Mraf-1, pc-myc/CDM8 and c-mos expression vector to establish transformed cell line MM-1, or pactEFcycE and p4E (v-ras expression vector) to establish transformed cell line CycExRas-1 and CycExRas-2. To establish cells transformed with c-myc under a doxycycline-responsive promoter and v-ras, 3Y1 cells were transfected with ptetcmyc, ptetrtTA and p4E, and grown in soft agar in the presence of 1 mg/ml of doxycycline. Colonies were picked up to establish the transformed cell line rtetCR-2. The cells were maintained in 10FBS ± DMEM containing 1 mg/ml of doxycycline.
Detection of apoptosis
Oligonucleosomal DNA ladders were detected essentially as described previously (Khwaja et al., 1997) . Cells were seeded in a tissue culture dish. The next day cells were rinsed twice with phosphate buered saline (PBS) containing 1 mM MgCl 2 and 1 mM CaCl 2 and once with DMEM supplemented with 0.5% fetal bovine serum (0.5FBS ± DMEM) and cultured in medium under the conditions described in the ®gures. Cells were then collected using trypsin and EDTA, and washed once with PBS. The cell pellets were lysed using 0.4 ml of extraction buer (0.5% Triton X-100, 10 mM Tris pH 8.0, 1 mM EDTA) for 20 min at 48C. The low molecular weight DNA-containing soluble fraction was isolated by centrifugation at 15 000 g for 10 min, and extracted with phenol/ chloroform three times. The DNA was precipitated with ethanol and resuspended in TE (10 mM Tris pH 8.0, 1 mM EDTA) containing 50 mg/ml RNase A. After a 2 h incubation at 378C, DNA was precipitated with polyethylene glycol, rinsed with ethanol and dissolved in TE. DNA sample from 4610 5 cells treated was run on a 1.3% agarose gel with molecular weight markers (100 bp DNA ladder purchased from New England BioLabs and HindIII digested lambda phage DNA) and visualized by ethidium bromide staining.
For¯ow cytometric analysis, whole cells in dishes were collected using trypsin/EDTA, ®xed in 50% methanol, and stained with 50 mg/ml propidium iodide. Cells were analysed using a Coulter EPICS.XL¯ow cytometer.
Reagents, antibodies and Western blotting
Rabbit anti c-Myc antibody was described previously (Tsuneoka et al., 1997) . Rabbit anti RCC1 antibody was a kind gift from Dr Nishimoto. Mouse anti-pan ras antibody (Ab-3, op40), mouse anti c-Myc antibody (clone 9E10), and PD098059 were purchased from Calbiochem-Novabiochem Corporation. Rabbit anti-phospho-MAPK/ERK (T202/ Y204) antibody was purchased from New England BioLabs. Rabbit anti MAPK/ERK antibody (no. sc-94) was purchased from Santa Cruz Biotechnology. Western blotting was done as described previously (Tsuneoka et al., 1997) .
